Raymond James analyst Jayson Bedford upgraded Edwards Lifesciences (EW) to Outperform from Market Perform with a $96 price target The company has “various opportunities” for better growth, which should drive multiple expansion for the shares, the analyst tells investors in a research note. The firm says Edwards’ transcatheter aortic valve replacement growth is improving, bolstered by the potential of asymptomatic adoption, while the company’s transcatheter mitral and tricuspid therapies business is “better positioned today than even before.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences Reports Strong Earnings and Growth
- Edwards Lifesciences price target raised to $92 from $88 at Evercore ISI
- Edwards Lifesciences price target raised to $104 from $94 at Goldman Sachs
- Edwards Lifesciences price target raised to $95 from $89 at RBC Capital
- Edwards Lifesciences price target raised to $90 from $85 at JPMorgan